Tofacitinib Global Market Opportunities And Strategies To 2032

Description

“Tofacitinib Global Market Opportunities And Strategies To 2032 ” from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global tofacitinib market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Where is the largest and fastest growing market for tofacitinib? How does the market relate to the overall economy, demography, and other similar markets? What forces will shape the market going forward? “The tofacitinib market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider tofacitinib market; and compares it with other markets.

The report covers the following chapters:

Introduction and Market Characteristics

Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by dosage strength, by indication and by distribution channel.

Key Trends

Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.

Macro-Economic Scenario

The report provides an analysis of the impact of the Russia-Ukraine war, impact of the COVID-19 pandemic and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the tofacitinib market.

Global Market Size and Growth

Global historic (2017-2022) and forecast (2022-2027, 2032F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.

Regional And Country Analysis

Historic (2017-2022) and forecast (2022-2027, 2032F) market values and growth and market share comparison by region and country.

Market Segmentation

Contains the market values (2017-2022) (2022-2027, 2032F) and analysis for each segment by drug class, by dosage strength, by indication and by distribution channel in the market. Historic (2017-2022) and forecast (2022-2027) and (2027-2032) market values and growth and market share comparison by region market.

Regional Market Size and Growth

Regional market size (2022), historic (2017-2022) and forecast (2022-2027,2032F) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

Competitive Landscape

Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.

Key Mergers and Acquisitions

Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.

Market Opportunities And Strategies

Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.

Conclusions And Recommendations

This section includes recommendations for tofacitinib providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.

Appendix

This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

1) By Drug Class: Antirheumatic; Janus kinase inhibitor; Immunosuppressant
2) By Dosage Strength: 5mg; 10mg; 11mg; 22mg
3) By Indication: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis; Other Indications
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Pfizer Inc; Beacon Pharmaceuticals PLC; Pharmascience Inc.; Qilu Pharmaceutical Co., Ltd; Delta Pharma Limited; Drug International Limited; Globe Group
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; tofacitinib indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1015

1. Executive Summary

1.1. Tofacitinib-Market Attractiveness And Macro economic Landscape

2. Table Of Contents

3. List Of Tables

4. List Of Figures

5. Report Structure

6. Market Characteristics

6.1. General Market Definition
6.2. Summary
6.3. Tofacitinib Market Definition And Segmentations
6.4. Market Segmentation By Drug Class
- 6.4.1. Antirheumatic
- 6.4.2. Janus Kinase Inhibitor
- 6.4.3. Immunosuppressant
6.5. Market Segmentation By Dosage Strength
- 6.5.1. 5mg
- 6.5.2. 10mg
- 6.5.3. 11mg
- 6.5.4. 22mg
6.6. Market Segmentation By Indication
- 6.6.1. Ulcerative Colitis
- 6.6.2. Rheumatoid Arthritis
- 6.6.3. Psoriasis
- 6.6.4. Other Indications
6.7. Market Segmentation By Distribution Channel
- 6.7.1. Hospital Pharmacy
- 6.7.2. Retail Pharmacy
- 6.7.3. Online Pharmacy

7. Major Market Trends

7.1. Development Of Advanced Products Such As Tofacitinib Ointment To Treat Rheumatoid Arthritis
7.2. Focus on Getting Approval Of Tofacitinib In New Geographies
7.3. Increase In Generic Drug Launches To Provide Affordable Treatment

8. Tofacitinib Market-Macro Economic Scenario

8.1. COVID-19KKKKK Impact On The Tofacitinib Market
8.2. Impact Of The War In Ukraine On The Tofacitinib Market
8.3. Impact Of High Inflation On The Tofacitinib Market

9. Global Market Size and Growth

9.1. Market Size
9.2. Historic Market Growth, 2017-2022, Value ($ Million)
9.3. Forecast Market Growth, 2022-2027, 2032F Value ($ Million)
9.4. Market Drivers
9.5. Market Restraints

10. Global Tofacitinib Market Segmentation

10.1. Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
10.2. Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
10.3. Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
10.4. Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

11. Tofacitinib Market, Regional and Country Analysis

11.1. Global Tofacitinib Market, By Region, Historic and Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
11.2. Global Tofacitinib Market, By Country, Historic and Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

12. Asia-Pacific Market

12.1. Summary
- 12.1.1. Market Overview
- 12.1.2. Region Information
- 12.1.3. Market Information
- 12.1.4. Background Information
- 12.1.5. Government Initiatives
- 12.1.6. Regulations
- 12.1.7. Regulatory Bodies
- 12.1.8. Major Associations
- 12.1.9. Taxes Levied
- 12.1.10. Corporate Tax Structure
- 12.1.11. Investments
- 12.1.12. Major Companies
12.2. Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.3. Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.4. Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.5. Asia-Pacific Tofacitinib Market: Country Analysis
12.6. China Market
12.7. Summary
- 12.7.1. Market Overview
- 12.7.2. Country Information
- 12.7.3. Market Information
- 12.7.4. Background Information
- 12.7.5. Government Initiatives
- 12.7.6. Regulations
- 12.7.7. Regulatory Bodies
- 12.7.8. Major Associations
- 12.7.9. Taxes Levied
- 12.7.10. Corporate Tax Structure
- 12.7.11. Investments
- 12.7.12. Major Companies
12.8. China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.9. China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.10. China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.11. India Market
12.12. India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.13. India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.14. India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.15. Japan Market
12.16. Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.17. Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.18. Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.19. Australia Market
12.20. Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.21. Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.22. Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.23. Indonesia Market
12.24. Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.25. Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.26. Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.27. South Korea Market
12.28. South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.29. South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
12.3. South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

13. Western Europe Market

13.1. Summary
- 13.1.1. Market Overview
- 13.1.2. Region Information
- 13.1.3. Market Information
- 13.1.4. Background Information
- 13.1.5. Government Initiatives
- 13.1.6. Regulations
- 13.1.7. Regulatory Bodies
- 13.1.8. Major Associations
- 13.1.9. Taxes Levied
- 13.1.10. Corporate tax structure
- 13.1.11. Investments
- 13.1.12. Major Companies
13.2. Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.3. Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.4. Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.5. Western Europe Tofacitinib Market: Country Analysis
13.6. UK Market
13.7. UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.8. UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.9. UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.10. Germany Market
13.11. Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.12. Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.13. Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.14. France Market
13.15. France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.16. France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
13.17. France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

14. Eastern Europe Market

14.1. Summary
- 14.1.1. Market Overview
- 14.1.2. Region Information
- 14.1.3. Market Information
- 14.1.4. Background Information
- 14.1.5. Government Initiatives
- 14.1.6. Regulations
- 14.1.7. Regulatory Bodies
- 14.1.8. Major Associations
- 14.1.9. Taxes Levied
- 14.1.10. Corporate Tax Structure
- 14.1.11. Investments
- 14.1.12. Major Companies
14.2. Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
14.3. Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
14.4. Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
14.5. Eastern Europe Tofacitinib Market: Country Analysis
14.6. Russia Market
14.7. Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
14.8. Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
14.9. Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

15. North America Market

15.1. Summary
- 15.1.1. Market Overview
- 15.1.2. Region Information
- 15.1.3. Market Information
- 15.1.4. Background Information
- 15.1.5. Government Initiatives
- 15.1.6. Regulations
- 15.1.7. Regulatory Bodies
- 15.1.8. Major Associations
- 15.1.9. Taxes Levied
- 15.1.10. Corporate Tax Structure
- 15.1.11. Investments
- 15.1.12. Major Companies
15.2. North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
15.3. North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
15.4. North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
15.5. North America Tofacitinib Market: Country Analysis
15.6. USA Market
15.7. Summary
- 15.7.1. Market Overview
- 15.7.2. Country Information
- 15.7.3. Market Information
- 15.7.4. Background Information
- 15.7.5. Government Initiatives
- 15.7.6. Regulations
- 15.7.7. Regulatory Bodies
- 15.7.8. Major Associations
- 15.7.9. Taxes Levied
- 15.7.10. Corporate Tax Structure
- 15.7.11. Investments
- 15.7.12. Major Companies
15.8. USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
15.9. USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
15.10. USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

16. South America Market

16.1. Summary
- 16.1.1. Market Overview
- 16.1.2. Region Information
- 16.1.3. Market Information
- 16.1.4. Background Information
- 16.1.5. Government Initiatives
- 16.1.6. Regulations
- 16.1.7. Regulatory Bodies
- 16.1.8. Major Associations
- 16.1.9. Taxes Levied
- 16.1.10. Corporate Tax Structure
- 16.1.11. Investments
- 16.1.12. Major Companies
16.2. South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
16.3. South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
16.4. South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
16.5. South America Tofacitinib Market: Country Analysis
16.6. Brazil Market
16.7. Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
16.8. Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
16.9. Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

17. Middle East Market

17.1. Summary
- 17.1.1. Market Overview
- 17.1.2. Region Information
- 17.1.3. Market Information
- 17.1.4. Background Information
- 17.1.5. Government Initiatives
- 17.1.6. Regulations
- 17.1.7. Regulatory Bodies
- 17.1.8. Major Associations
- 17.1.9. Taxes Levied
- 17.1.10. Corporate Tax Structure
- 17.1.11. Investments
- 17.1.12. Major Companies
17.2. Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
17.3. Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
17.4. Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

18. Africa Market

18.1. Summary
- 18.1.1. Market Overview
- 18.1.2. Region Information
- 18.1.3. Market Information
- 18.1.4. Background Information
- 18.1.5. Government Initiatives
- 18.1.6. Regulations
- 18.1.7. Regulatory Bodies
- 18.1.8. Major Associations
- 18.1.9. Taxes Levied
- 18.1.10. Corporate Tax Structure
- 18.1.11. Major Companies
18.2. Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
18.3. Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)
18.4. Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017-2023, 2027F, 2032F, Value ($ Million)

19. Competitive Landscape and Company Profiles

19.1. Company Profiles
19.2. Pfizer Inc
- 19.2.1. Company Overview
- 19.2.2. Products And Services
- 19.2.3. Business Strategy
- 19.2.4. Financial Overview
19.3. Beacon Pharmaceuticals PLC
- 19.3.1. Company Overview
- 19.3.2. Products And Services
- 19.3.3. Business Strategy
- 19.3.4. Financial Overview
19.4. Pharmascience Inc.
- 19.4.1. Company Overview
- 19.4.2. Products And Services
- 19.4.3. Business Strategy
- 19.4.4. Financial Overview
19.5. Qilu Pharmaceutical Co., Ltd
- 19.5.1. Company Overview
- 19.5.2. Products And Services
- 19.5.3. Business Strategy
- 19.5.4. Financial Overview
19.6. Delta Pharma Limited
- 19.6.1. Company Overview
- 19.6.2. Products And Services
- 19.6.3. Financial Overview

20. Key Mergers And Acquisitions

20.1. Sun Pharma Acquired Concert Pharmaceuticals
20.2. GSK Acquired Sierra Oncology
20.3. Pfizer Acquired Arena Pharmaceuticals

21. Opportunities And Strategies

21.1. Global Tofacitinib Market In 2027-Countries Offering Most New Opportunities
21.2. Global Tofacitinib Market In 2027-Segments Offering Most New Opportunities
21.3. Global Tofacitinib Market In 2027-Growth Strategies
- 21.3.1. Market Trend Based Strategies
- 21.3.2. Competitor Strategies

22. Tofacitinib Market, Conclusions And Recommendations

22.1. Conclusions
22.2. Recommendations
- 22.2.1. Product
- 22.2.2. Place
- 22.2.3. Price
- 22.2.4. Promotion
- 22.2.5. People

23. Appendix

23.1. Geographies Covered
23.2. Market Data Sources
23.3. Research Methodology
23.4. Currencies
23.5. The Business Research Company
23.6. Copyright and Disclaimer